NCT07171112View on ClinicalTrials.gov

Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2028

Conditions
Pancreatitis, ChronicPancreatitis, AcuteRecurrent Acute PancreatitisSmoking (Tobacco) Addiction
Interventions
DRUG

Standard Varenicline Dosing (1 mg BID)

Varenicline PO (oral) 1mg twice daily

DRUG

Bupropion 150 mg twice daily

Bupropion 150 mg PO twice daily

DRUG

Increased Varenicline Dosing (1mg TID)

Varenicline 1mg PO (oral) three times daily

Trial Locations (1)

55902

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER